Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
About eight percent of all human tumors (including 50% of melanomas) carry gain-of-function mutations in the BRAF oncogene. Mutated BRAF and subsequent hyperactivation of the MAPK signaling pathway has motivated the use of MAPK-targeted therapies for these tumors. Despite great promise, however, MAP...
Main Authors: | Mehwish Khaliq, Mohammad Fallahi-Sichani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1480 |
Similar Items
-
Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
by: Wenjing Chen, et al.
Published: (2023-10-01) -
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01) -
BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
by: Mattia Garutti, et al.
Published: (2022-12-01) -
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
by: Taku Fujimura, et al.
Published: (2019-09-01) -
Targeting Oncogenic BRAF: Past, Present, and Future
by: Aubhishek Zaman, et al.
Published: (2019-08-01)